Toxic Epidermal Necrolysis
📧 Sign up to get email alerts when something new happens for Toxic Epidermal Necrolysis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-01-16Clinical Trial Update: Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
The clinical trial NCT03585946 investigating outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis has been withdrawn, with no…
-
CLINICAL_TRIALS trial_result · 2025-12-31Clinical Trial Update: G-CSF in the Treatment of Toxic Epidermal Necrolysis [Phase 4]
Phase 4 clinical trial update evaluating granulocyte colony-stimulating factor (filgrastim) for toxic epidermal necrolysis and Stevens-Johns…
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: NATIENS: Optimal Management and Mechanisms of SJS/TEN [Phase 3]
Phase 3 clinical trial NATIENS for optimal management and mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis has complete…
-
CLINICAL_TRIALS trial_result · 2025-09-16Clinical Trial Update: Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN [NA]
A completed clinical trial assessed the efficacy of tofacitinib in patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, wi…
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. [Phase 1, Phase 2]
A Phase 1/2 trial is investigating anti-CD38+ monoclonal antibodies as a new therapeutic target for Toxic Epidermal Necrolysis, with the stu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-08-01Clinical Trial Update: LYell SYndrome MEsenchymal Stromal Cells Treatment [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating adipose-derived mesenchymal stromal cells for Lyell syndrome/toxic epidermal necrolysis; recruitment i…
-
CLINICAL_TRIALS trial_result · 2024-07-29Clinical Trial Update: SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors (ICIs) vs. Non-ICIs
Completed clinical trial comparing immune checkpoint inhibitors versus non-ICI therapies for cutaneous adverse events, including Stevens-Joh…
-
CLINICAL_TRIALS research · 2024-07-08Clinical Trial Update: Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the safety and potential efficacy of a cell therapy in patients with cicatricial conjunctivitis and re…
-
CLINICAL_TRIALS research · 2024-05-08Clinical Trial Update: Severe Bullous Drug Eruption and Filgrastim [Phase 2, Phase 3]
The document announces ongoing Phase 2 and Phase 3 recruitment for a clinical trial evaluating filgrastim in patients with toxic epidermal n…
-
CLINICAL_TRIALS research · 2019-02-18Clinical Trial Update: Severe Cutaneous Adverse Reactions in Thailand
This clinical trial update from Thailand reports on severe cutaneous adverse reactions, including Stevens-Johnson Syndrome and Toxic Epiderm…
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis [NA]
This clinical trial update describes a study of minor salivary gland transplantation for cicatricial conjunctivitis, sponsored by National T…
-
CLINICAL_TRIALS withdrawal · 2017-04-07Clinical Trial Update: Topical Infliximab in Autoimmune Eyes With Keratoprosthesis [Phase 1, Phase 2]
A Phase 1/2 clinical trial of topical infliximab for autoimmune eye conditions with keratoprosthesis has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2016-11-30Clinical Trial Update: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Palifermin for Toxic Epidermal Necrolysis and Stevens-Johnson syndrome was terminated, with results po…
-
CLINICAL_TRIALS trial_result · 2014-07-02Clinical Trial Update: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. [Phase 3]
Phase III clinical trial of NPB-01 for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis unresponsive to corticosteroids has completed…
-
CLINICAL_TRIALS withdrawal · 2013-04-26Clinical Trial Update: Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) [Phase 2]
A Phase 2 study investigating a potential new treatment for toxic epidermal necrolysis has been withdrawn.